Table 3.

Prevalence of anti-nuclear antibodies in biliary atresia patients and non-biliary atresia controls n (%)

Variable	BA, n = 124	Other liver diseases1, n = 92	Healthy, n = 48
ANA, by IIF	14 (11.3)c	3 (3.3)	2 (4.2)
Fluorescence patterns
Homogeneous	3 (2.4)	0 (0)	0 (0)
Speckled	3 (2.4)	0 (0)	1 (2.1)
Nucleolar	3 (2.4)	0 (0)	1 (2.1)
Nuclear dots	1 (0.8)	0 (0)	0 (0)
Centrosome	1 (0.8)	0 (0)	0 (0)
Cytoplasm	1 (0.8)	0 (0)	0 (0)
Ring or rod Golgi	1 (0.8)	2 (2.2)	0 (0)
Centromere	1 (0.8)	0 (0)	0 (0)
Spindle apparatus	0 (0)	1 (1.1)	0 (0)
Specific ANA2, by line-blot
SSA	1 (0.8)	0 (0)	0 (0)
Ro-52	5 (4.0)	2 (2.2)	2 (4.2)
CENP B	4 (3.2)	1 (1.1)	0 (0)
dsDNA	3 (2.4)	0 (0)	0 (0)

¹Choledochal cysts, transient cholestasis of unknown origin, and neonatal intrahepatic cholestasis caused by citrin deficiency were included as disease controls;

²Specific ANAs included 12 different antibodies, with only SSA, Ro-52, CENP B, and dsDNA positive in the study.

^cP < 0.05 vs other liver diseases. ANA: Anti-nuclear antibody; BA: Biliary atresia; IIF: Indirect immunofluorescence.